Amelioration of Systemic Fibrosis in Mice by Angiotensin II Receptor Blockade

Arthritis and Rheumatism

Volumn 65, Issue 5, 2013, Pages 1367-1377

  Marut, Wioleta ^a   Kavian, Niloufar ^a   Servettaz, Amélie ^a,b   Hua Huy, Thong ^a   Nicco, Carole ^a   Chéreau, Christiane ^a   Weill, Bernard ^a   Dinh Xuan, Anh Tuan ^a   Batteux, Frédéric ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b SERVICE DE DERMATOLOGIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; ALPHA SMOOTH MUSCLE ACTIN; ANGIOTENSIN 1 RECEPTOR; AUTOANTIBODY; COLLAGEN; DNA TOPOISOMERASE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; IMMUNOGLOBULIN G ANTIBODY; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 13; IRBESARTAN; NITRITE; SMAD2 PROTEIN; SMAD3 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; FIBROBLAST; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LUNG FIBROSIS; MOUSE; NITROSATIVE STRESS; NONHUMAN; ONCOGENE H RAS; PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN FIBROSIS; SKINFOLD THICKNESS; SPLEEN CELL; SYSTEMIC SCLEROSIS; T LYMPHOCYTE;

ADMINISTRATION, ORAL; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BIOLOGICAL MARKERS; BIPHENYL COMPOUNDS; BREATH TESTS; DISEASE MODELS, ANIMAL; FEMALE; FIBROSIS; HYPOCHLOROUS ACID; INJECTIONS, INTRADERMAL; LUNG; MICE; MICE, INBRED BALB C; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; OXIDANTS; PULMONARY FIBROSIS; SCLERODERMA, SYSTEMIC; SKIN; TETRAZOLES; TYROSINE;

EID: 84876542539     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.37873     Document Type: Article

References (53)

1. Dooley A, Bruckdorfer KR, Abraham DJ,. Modulation of fibrosis in systemic sclerosis by nitric oxide and antioxidants. Cardiol Res Pract 2012; 2012: 521958.
2. Malcarne VL, Hansdottir I, McKinney A, Upchurch R, Greenbergs HL, Henstorf GH, et al. Medical signs and symptoms associated with disability, pain, and psychosocial adjustment in systemic sclerosis. J Rheumatol 2007; 34: 359-67.
3. Kawaguchi Y, Takagi K, Hara M, Fukasawa C, Sugiura T, Nishimagi E, et al. Angiotensin II in the lesional skin of systemic sclerosis patients contributes to tissue fibrosis via angiotensin II type 1 receptors. Arthritis Rheum 2004; 50: 216-26.
4. Stawski LS, Han R, Bujor AM, Trojanowska M,. Angiotensin II induces skin fibrosis: a novel mouse model of dermal fibrosis. Arthritis Res Ther 2012; 14: R194.
5. Ohtani R, Ohashi Y, Muranaga K, Itoh N, Okamoto H,. Changes in activity of the renin-angiotensin system of the rat by induction of acute inflammation. Life Sci 1989; 44: 237-41.
6. Ohashi N, Urushihara M, Satou R, Kobori H,. Glomerular angiotensinogen is induced in mesangial cells in diabetic rats via reactive oxygen species-ERK/JNK pathways. Hypertens Res 2010; 33: 1174-81.
7. Uhal BD, Kim JK, Li X, Molina-Molina M,. Angiotensin-TGF-β1 crosstalk in human idiopathic pulmonary fibrosis: autocrine mechanisms in myofibroblasts and macrophages. Curr Pharm Des 2007; 13: 1247-56.
8. Riemekasten G, Philippe A, Nather M, Slowinski T, Muller DN, Heidecke H, et al. Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. Ann Rheum Dis 2011; 70: 530-6.
9. Fukasawa H, Furuya R, Ishigaki S, Kinoshita N, Isobe S, Fujigaki Y,. Hyponatremia in a patient with scleroderma renal crisis: a potential role of activated renin-angiotensin system. BMC Nephrol 2012; 13: 47.
10. De Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T,. International Union of Pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000; 52: 415-72.
11. Mezzano SA, Ruiz-Ortega M, Egido J,. Angiotensin II and renal fibrosis. Hypertension 2001; 38: 635-8.
12. Watanabe T, Barker TA, Berk BC,. Angiotensin II and the endothelium: diverse signals and effects. Hypertension 2005; 45: 163-9.
13. Hunyady L, Catt KJ,. Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. Mol Endocrinol 2006; 20: 953-70.
14. Chappell MC,. Angiotensin-converting enzyme 2 autoantibodies: further evidence for a role of the renin-angiotensin system in inflammation. Arthritis Res Ther 2010; 12: 128.
15. Wang W, Huang XR, Canlas E, Oka K, Truong LD, Deng C, et al. Essential role of Smad3 in angiotensin II-induced vascular fibrosis. Circ Res 2006; 98: 1032-9.
16. Dragun D, Muller DN, Brasen JH, Fritsche L, Nieminen-Kelha M, Dechend R, et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 2005; 352: 558-69.
17. Wallukat G, Homuth V, Fischer T, Lindschau C, Horstkamp B, Jupner A, et al. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest 1999; 103: 945-52.
18. Xia Y, Ramin SM, Kellems RE,. Potential roles of angiotensin receptor-activating autoantibody in the pathophysiology of preeclampsia. Hypertension 2007; 50: 269-75.
19. Dooley A, Gao B, Bradley N, Abraham DJ, Black CM, Jacobs M, et al. Abnormal nitric oxide metabolism in systemic sclerosis: increased levels of nitrated proteins and asymmetric dimethylarginine. Rheumatology (Oxford) 2006; 45: 676-84.
20. Walker KM, Pope J,. Treatment of systemic sclerosis complications: what to use when first-line treatment fails-a consensus of systemic sclerosis experts. Semin Arthritis Rheum 2012; 42: 42-55.
21. Servettaz A, Goulvestre C, Kavian N, Nicco C, Guilpain P, Chereau C, et al. Selective oxidation of DNA topoisomerase 1 induces systemic sclerosis in the mouse. J Immunol 2009; 182: 5855-64.
22. Servettaz A, Goulvestre C, Kavian N, Nicco C, Guilpain P, Chereau C, et al. Selective oxidation of DNA topoisomerase 1 induced systemic sclerosis in the mouse. J Immunol 2009; 182: 5855-64.
23. Dalle-Donne I, Rossi R, Giustarini D, Gagliano N, Lusini L, Milzani A, et al. Actin carbonylation: from a simple marker of protein oxidation to relevant signs of severe functional impairment. Free Radic Biol Med 2001; 1: 1075-83.
24. Burdick MD, Murray LA, Keane MP, Xue YY, Zisman DA, Belperio JA, et al. CXCL11 attenuates bleomycin-induced pulmonary fibrosis via inhibition of vascular remodeling. Am J Respir Crit Care Med 2005; 171: 261-8.
25. Sue RD, Belperio JA, Burdick MD, Murray LA, Xue YY, Dy MC, et al. CXCR2 is critical to hyperoxia-induced lung injury. J Immunol 2004; 172: 3860-8.
26. Servettaz A, Kavian N, Nicco C, Deveaux V, Chereau C, Wang A, et al. Targeting the cannabinoid pathway limits the development of fibrosis and autoimmunity in a mouse model of systemic sclerosis. Am J Pathol 2010; 177: 187-96.
27. 2NQ prevents HOCl-induced systemic sclerosis in mouse. J Invest Dermatol 2012; 132: 1125-32.
28. Kavian N, Servettaz A, Mongaret C, Wang A, Nicco C, Chereau C, et al. Targeting ADAM-17/Notch signaling abrogates the development of systemic sclerosis in a murine model. Arthritis Rheum 2010; 62: 3477-87.
29. Sastry KV, Moudgal RP, Mohan J, Tyagi JS, Rao GS,. Spectrophotometric determination of serum nitrite and nitrate by copper-cadmium alloy. Anal Biochem 2002; 306: 79-82.
30. Delclaux C, Dinh-Xuan AT,. Art-and artefacts-of exhaled NO measurement in asthma. Rev Mal Respir 2005; 22: 209-11. In French.
31. Smaldone S, Olivieri J, Gusella GL, Moroncini G, Gabrielli A, Ramirez F,. Ha-Ras stabilization mediates pro-fibrotic signals in dermal fibroblasts. Fibrogenesis Tissue Repair 2011; 4: 8.
32. Rosenbloom J, Saitta B, Gaidarova S, Sandorfi N, Rosenbloom JC, Abrams WR, et al. Inhibition of type I collagen gene expression in normal and systemic sclerosis fibroblasts by a specific inhibitor of geranylgeranyl transferase I. Arthritis Rheum 2000; 43: 1624-32.
33. Shimizu K, Ogawa F, Muroi E, Hara T, Komura K, Bae SJ, et al. Increased serum levels of nitrotyrosine, a marker for peroxynitrite production, in systemic sclerosis. Clin Exp Rheumatol 2007; 25: 281-6.
34. Tiev KP, Hua-Huy T, Kettaneh A, Allanore Y, Le-Dong NN, Duong-Quy S, et al. Alveolar concentration of nitric oxide predicts pulmonary function deterioration in scleroderma. Thorax 2012; 67: 157-63.
35. Gruschwitz MS, Hornstein OP, von den Driesch P,. Correlation of soluble adhesion molecules in the peripheral blood of scleroderma patients with their in situ expression and with disease activity. Arthritis Rheum 1995; 38: 184-9.
36. Yang F, Chung AC, Huang XR, Lan HY,. Angiotensin II induces connective tissue growth factor and collagen I expression via transforming growth factor-β-dependent and -independent Smad pathways: the role of Smad3. Hypertension 2009; 54: 877-84.
37. Ren X, Guan G, Liu G,. Irbesartan ameliorates diabetic nephropathy by reducing the expression of connective tissue growth factor and α-smooth-muscle actin in the tubulointerstitium of diabetic rats. Pharmacology 2009; 83: 80-7.
38. Queisser N, Fazeli G, Schupp N,. Superoxide anion and hydrogen peroxide-induced signaling and damage in angiotensin II and aldosterone action. Biol Chem 2010; 391: 1265-79.
39. Lijnen PJ, van Pelt JF, Fagard RH,. Stimulation of reactive oxygen species and collagen synthesis by angiotensin II in cardiac fibroblasts. Cardiovasc Ther 2012; 30: e1-8.
40. Yahata Y, Shirakata Y, Tokumaru S, Yang L, Dai X, Tohyama M, et al. A novel function of angiotensin II in skin wound healing: induction of fibroblast and keratinocyte migration by angiotensin II via heparin-binding epidermal growth factor (EGF)-like growth factor-mediated EGF receptor transactivation. J Biol Chem 2006; 281: 13209-16.
41. Martinez-Salgado C, Fuentes-Calvo I, Garcia-Cenador B, Santos E, Lopez-Novoa JM,. Involvement of H- and N-Ras isoforms in transforming growth factor-β1-induced proliferation and in collagen and fibronectin synthesis. Exp Cell Res 2006; 312: 2093-106.
42. c-src. J Biol Chem 1996; 271: 10329-33.
43. Sato S, Fujimoto M, Hasegawa M, Takehara K,. Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells. Arthritis Rheum 2004; 50: 1918-27.
44. Needleman BW, Wigley FM, Stair RW,. Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor α, and interferon-γ levels in sera from patients with scleroderma. Arthritis Rheum 1992; 35: 67-72.
45. Iborra S, Soto M, Stark-Aroeira L, Castellano E, Alarcon B, Alonso C, et al. H-ras and N-ras are dispensable for T-cell development and activation but critical for protective Th1 immunity. Blood 2011; 117: 5102-11.
46. Sambo P, Baroni SS, Luchetti M, Paroncini P, Dusi S, Orlandini G, et al. Oxidative stress in scleroderma: maintenance of scleroderma fibroblast phenotype by the constitutive up-regulation of reactive oxygen species generation through the NADPH oxidase complex pathway. Arthritis Rheum 2001; 44: 2653-64.
47. Servettaz A, Guilpain P, Goulvestre C, Chereau C, Hercend C, Nicco C, et al. Radical oxygen species production induced by advanced oxidation protein products predicts clinical evolution and response to treatment in systemic sclerosis. Ann Rheum Dis 2007; 66: 1202-9.
48. Takagi K, Kawaguchi Y, Hara M, Sugiura T, Harigai M, Kamatani N,. Serum nitric oxide (NO) levels in systemic sclerosis patients: correlation between NO levels and clinical features. Clin Exp Immunol 2003; 134: 538-44.
49. Urtasun R, Conde de la Rosa L, Nieto N,. Oxidative and nitrosative stress and fibrogenic response. Clin Liver Dis 2008; 12: 769-90, viii.
50. Forstermann U, Gath I, Schwarz P, Closs EI, Kleinert H,. Isoforms of nitric oxide synthase: properties, cellular distribution and expressional control. Biochem Pharmacol 1995; 50: 1321-32.
51. Sigusch HH, Campbell SE, Weber KT,. Angiotensin II-induced myocardial fibrosis in rats: role of nitric oxide, prostaglandins and bradykinin. Cardiovasc Res 1996; 31: 546-54.
52. Fan Q, Liao J, Kobayashi M, Yamashita M, Gu L, Gohda T, et al. Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice. Nephrol Dial Transplant 2004; 19: 3012-20.
53. Tiev KP, Le-Dong NN, Duong-Quy S, Hua-Huy T, Cabane J, Dinh-Xuan AT,. Exhaled nitric oxide, but not serum nitrite and nitrate, is a marker of interstitial lung disease in systemic sclerosis. Nitric Oxide 2009; 20: 200-6.